CN109963591B - B7h3抗体-药物偶联物及其医药用途 - Google Patents

B7h3抗体-药物偶联物及其医药用途 Download PDF

Info

Publication number
CN109963591B
CN109963591B CN201880004425.6A CN201880004425A CN109963591B CN 109963591 B CN109963591 B CN 109963591B CN 201880004425 A CN201880004425 A CN 201880004425A CN 109963591 B CN109963591 B CN 109963591B
Authority
CN
China
Prior art keywords
antibody
ser
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880004425.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109963591A (zh
Inventor
顾津明
叶鑫
杨柳青
梁金栋
蒋贵阳
陶维康
张连山
应华
张玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Hengbang Pharmaceutical Co ltd
Hansen Shanghai Health Technology Co ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109963591A publication Critical patent/CN109963591A/zh
Application granted granted Critical
Publication of CN109963591B publication Critical patent/CN109963591B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201880004425.6A 2017-08-04 2018-08-03 B7h3抗体-药物偶联物及其医药用途 Active CN109963591B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710660432 2017-08-04
CN2017106604329 2017-08-04
PCT/CN2018/098480 WO2019024911A1 (fr) 2017-08-04 2018-08-03 Conjugué anticorps anti-b7h3-médicament et son utilisation médicale

Publications (2)

Publication Number Publication Date
CN109963591A CN109963591A (zh) 2019-07-02
CN109963591B true CN109963591B (zh) 2023-04-04

Family

ID=65232283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004425.6A Active CN109963591B (zh) 2017-08-04 2018-08-03 B7h3抗体-药物偶联物及其医药用途

Country Status (3)

Country Link
CN (1) CN109963591B (fr)
TW (1) TW201909926A (fr)
WO (1) WO2019024911A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018161872A1 (fr) * 2017-03-06 2018-09-13 江苏恒瑞医药股份有限公司 Anticorps anti-b7-h3, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée
US20210347894A1 (en) * 2018-09-30 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
WO2021190480A1 (fr) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 Conjugué anticorps-médicament et son utilisation médicale
WO2021190586A1 (fr) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Conjugué d'anticorps anti-b7h3 et d'analogue d'exatecan et utilisation pharmaceutique de celui-ci
CA3175733A1 (fr) * 2020-03-25 2021-09-30 Shanghai Hengrui Pharmaceutical Co., Ltd. Composition pharmaceutique comprenant un conjugue anticorps-medicament et son utilisation
CN115279781A (zh) * 2020-03-26 2022-11-01 上海翰森生物医药科技有限公司 抗体药物偶联物及其医药用途
WO2022104692A1 (fr) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anticorps modifié, conjugué anticorps-médicament et son utilisation
IL305847A (en) 2021-03-26 2023-11-01 Innate Pharma Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
CA3218793A1 (fr) 2021-06-09 2022-12-15 Laurent Gauthier Proteines multispecifiques se liant a nkp46, recepteur de cytokine, antigene tumoral et cd16a
WO2022258678A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a
WO2022258691A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a
CN113933373B (zh) * 2021-12-16 2022-02-22 成都健数科技有限公司 一种利用质谱数据确定有机物结构的方法和系统
WO2023236949A1 (fr) * 2022-06-07 2023-12-14 映恩生物制药（苏州）有限公司 Conjugué anticorps-médicament anti-b7h4 et son utilisation
WO2024114525A1 (fr) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 Protéine de liaison b7-h3 et son utilisation
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CA2990408A1 (fr) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Conjugues anticorps-principe actif (adc) d'inhibiteurs de ksp avec des anticorps anti-b7h3
TW201718020A (zh) * 2015-06-23 2017-06-01 拜耳製藥公司 Ksp抑制劑與抗b7h3抗體之抗體藥物結合物(adc)
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN110090306A (zh) * 2018-01-31 2019-08-06 江苏恒瑞医药股份有限公司 双醛连接臂的配体-药物偶联物、其制备方法及其应用
CN110305213A (zh) * 2018-11-09 2019-10-08 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113121639A (zh) * 2019-12-30 2021-07-16 江苏恒瑞医药股份有限公司 澳瑞他汀类似物及其偶联物、其制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687021B (zh) * 2007-03-22 2013-04-17 斯隆-凯特琳癌症研究院 单克隆抗体8h9的应用
CN106715469B (zh) * 2014-08-27 2021-10-22 纪念斯隆-凯特琳癌症中心 抗体、组合物和用途
EP4180455A1 (fr) * 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Procédé de fabrication sélective d'un conjugué anticorps-médicament
SG10201914119TA (en) * 2016-06-08 2020-02-27 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687945A (zh) * 2011-04-25 2014-03-26 第一三共株式会社 抗-b7-h3抗体
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CA2990408A1 (fr) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Conjugues anticorps-principe actif (adc) d'inhibiteurs de ksp avec des anticorps anti-b7h3
TW201718020A (zh) * 2015-06-23 2017-06-01 拜耳製藥公司 Ksp抑制劑與抗b7h3抗體之抗體藥物結合物(adc)
CN109937212A (zh) * 2017-03-31 2019-06-25 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN110090306A (zh) * 2018-01-31 2019-08-06 江苏恒瑞医药股份有限公司 双醛连接臂的配体-药物偶联物、其制备方法及其应用
CN110305213A (zh) * 2018-11-09 2019-10-08 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN113121639A (zh) * 2019-12-30 2021-07-16 江苏恒瑞医药股份有限公司 澳瑞他汀类似物及其偶联物、其制备方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3 Positive Tumor Cells and Tumor Vasculature;Steven Seaman等;《Cancer Cell》;20170410;第31卷(第4期);第501–515 *
The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is;Nathan M. Kendsersky等;《Clin Cancer Res》;20210515;第27卷(第10期);第2938–2946页 *

Also Published As

Publication number Publication date
CN109963591A (zh) 2019-07-02
WO2019024911A1 (fr) 2019-02-07
TW201909926A (zh) 2019-03-16

Similar Documents

Publication Publication Date Title
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP7057843B2 (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
JP7158403B2 (ja) Ｂ７－ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
JP2023002706A (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN112533955B (zh) 抗b7-h3抗体
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2020505386A (ja) 抗ｐｄ−１抗体およびその使用
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
WO2018166507A1 (fr) Nouvelle protéine de fusion bifonctionnelle recombinante, son procédé de préparation et son utilisation
CN113906053B (zh) 抗cea抗体及其应用
CN111196854A (zh) Ox40抗体及其制备方法和应用
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
WO2023143535A1 (fr) Anticorps ciblant il-18bp et son utilisation
JP2021531825A (ja) 葉酸受容体アルファに特異的な抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
CN113045659B (zh) 抗cd73人源化抗体
JP2024516581A (ja) 抗ヒトｃｄ７３抗体およびその適用
JP2022542088A (ja) 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
CN114981301A (zh) Pd1和vegfr2双结合剂
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
CN113597432B (zh) 抗EpCAM抗体及其应用
WO2023109962A1 (fr) Anticorps se liant au cd73 humain, son procédé de préparation et son utilisation
WO2023190465A1 (fr) Anticorps anti-sema7a humain
TW202405017A (zh) 抗cd40抗體和抗pd-l1×cd40雙特異抗體及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231130

Address after: Room 101, No. 1158 Haike Road, No. 287 Xiangke Road, Pudong New Area Free Trade Pilot Zone, Shanghai, October 2012

Patentee after: Hansen (Shanghai) Health Technology Co.,Ltd.

Patentee after: Changzhou Hengbang Pharmaceutical Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right